Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Med Chem ; 43(20): 3736-45, 2000 Oct 05.
Artigo em Inglês | MEDLINE | ID: mdl-11020288

RESUMO

Modification of the potent fibrinogen receptor (alpha(IIb)beta(3)) antagonist 1 generated compounds with high affinity for the vitronectin receptor alpha(v)beta(3). Sequential modification of the basic N-terminus of 1 led to the identification of the 5,6,7, 8-tetrahydro[1,8]naphthyridine moiety (THN) as a lipophilic, moderately basic N-terminus that provides molecules with excellent potency and selectivity for the integrin receptor alpha(v)beta(3). The THN-containing analogue 5 is a potent inhibitor of bone resorption in vitro and in vivo. In addition, the identification of a novel, nonpeptide radioligand with high affinity to alpha(v)beta(3) is also reported.


Assuntos
Naftiridinas/síntese química , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/antagonistas & inibidores , Propionatos/síntese química , Sulfonamidas/síntese química , Animais , Reabsorção Óssea/patologia , Linhagem Celular , Técnicas de Cultura , Humanos , Ligantes , Naftiridinas/química , Naftiridinas/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Propionatos/química , Propionatos/farmacologia , Ratos , Ratos Sprague-Dawley , Sulfonamidas/química , Sulfonamidas/farmacologia
2.
Curr Pharm Des ; 6(10): 973-89, 2000 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-10828297

RESUMO

Non-Invasive Radiotracer Imaging (NIRI) uses either short-lived positron-emitting isotopes, such as 11C and 18F, for Positron Emis ion Tomography (PET) or single photon emitting nuclides, e.g., 123I, which provide images using planar imaging or Single-Photon Emission Computed Tomography (SPECT). These high-resolution imaging modalities provide anatomical distribution and localization of radiolabeled drugs, which can be used to generate real time receptor occupancy and off-rate studies in humans. This can be accomplished by either isotopically labeling a potential new drug (usually with 11C), or indirectly by studying how the unlabelled drug inhibits specific radioligand binding in vivo. Competitive blockade studies can be accomplished using a radiolabeled analogue which binds to the site of interest, rather than a radiolabeled version of the potential drug. Imaging, particularly PET imaging, can be used to demonstrate the effect of a drug through a biochemical marker of processes such as glucose metabolism or blood flow. NIRI as a development tool in the pharmaceutical industry is gaining increased acceptance as its unique ability to provide such critical information in human subjects is recognized. This section will review recent examples that illustrate the utility of NIRI, principally PET, in drug development, and the potential of imaging advances in the development of cancer drugs and gene therapy. Finally, we provide a brief overview of the design of new radiotracers for novel targets.


Assuntos
Desenho de Fármacos , Farmacologia/tendências , Cintilografia , Compostos Radiofarmacêuticos , Animais , Humanos , Tomografia Computadorizada de Emissão , Tomografia Computadorizada de Emissão de Fóton Único
3.
Curr Opin Chem Biol ; 3(4): 388-94, 1999 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10419855

RESUMO

Improved communication and cooperation between research-driven drug companies and academic positron emission tomography (PET) centers, coupled with improvements in PET camera resolution, the availability of small animal PET cameras and a growing list of neuroreceptor-specific PET tracers, have all contributed to a substantial increase in the use and value of PET as a tool in central nervous system drug discovery and development.


Assuntos
Desenho de Fármacos , Células Receptoras Sensoriais/metabolismo , Tomografia Computadorizada de Emissão/métodos , Animais , Sistema Nervoso Central/diagnóstico por imagem , Sistema Nervoso Central/efeitos dos fármacos , Sistema Nervoso Central/metabolismo , Humanos
4.
J Nucl Med ; 39(7): 1209-13, 1998 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-9669396

RESUMO

UNLABELLED: Antagonists of the angiotensin II AT1 receptor subtype have been recently introduced for treatment of arterial hypertension and for pharmacological studies of these receptors. The purpose of this work was to label such an antagonist with 11C and test the applicability of the radioligand for PET studies. METHODS: The potent and selective nonpeptide AT1 antagonist L-159,884 was labeled with 11C and injected intravenously into six dogs. Renal accumulation and kinetics of the radioligand were imaged with PET at baseline and after receptor blockade with 1 mg/kg MK-996. Time-activity curves were derived from the renal cortex and were analyzed by the Gjedde-Patlak plot to obtain the influx rate constant of the radioligand. RESULTS: There was selective radioligand binding in the kidneys, mainly located in the cortex. Within the time interval between 95 and 115 min postinjection, the radioactivity retained in the kidneys was 109 +/- 27 and 42 +/- 4 nCi/ml/mCi of the injected dose for the control and inhibition studies, respectively. The influx rate constant of the radioligand decreased from a baseline of 0.0298 +/- 0.0156 to a post-MK-996 value of 0.0098 +/- 0.0052. CONCLUSION: These results demonstrate distinct binding of 11C-L-159,884 in the renal cortex with a specific binding component suitable for quantitative PET imaging of angiotensin II/AT1 receptors.


Assuntos
Angiotensina II/antagonistas & inibidores , Radioisótopos de Carbono , Imidazóis , Córtex Renal/diagnóstico por imagem , Piridinas , Receptores de Angiotensina/metabolismo , Tomografia Computadorizada de Emissão , Antagonistas de Receptores de Angiotensina , Animais , Cães , Estudos de Viabilidade , Córtex Renal/metabolismo , Ensaio Radioligante , Fatores de Tempo
5.
J Pharmacol Exp Ther ; 285(3): 1317-26, 1998 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-9618439

RESUMO

A critical function of fibrinogen in hemostasis and thrombosis is to mediate platelet aggregation by binding selectively to an activated form of glycoprotein (GP) IIb/IIIa. Although numerous peptide and nonpeptide fibrinogen receptor antagonists have been described, their binding selectivity for resting and activated platelets has not been explored. Therefore, dissociation constants of GP IIb/IIIa antagonists for two biochemically separated forms of purified GP IIb/IIIa and for resting and activated platelets were determined by competitive displacement of the dansyl fluorophore containing GP IIb/IIIa antagonist L-736,622. Also, coating either form of the purified GP IIb/IIIa onto yttrium silicate scintillation proximity assay fluomicrospheres produced an activated form of the receptor, whose binding affinity for GP IIb/IIIa antagonists was measured conveniently by competition with the arginine-glycine-aspartic acid (RGD) containing heptapeptide [125I]L-692,884. In addition, direct binding measurements with radiolabeled GP IIb/IIIa antagonists also were performed on resting and activated platelets. We identified two classes of compounds. One class binds to both forms of GP IIb/IIIa, as well as resting and activated platelets, with similar Kd values (e.g., L-736,622 and Echistatin). The other class of compounds binds with much higher affinity to the activated form of GP IIb/IIIa (purified or on platelets) as compared with the resting form (e.g., L-734,217, MK-852, tirofiban and L-692,884). Selective antagonists, like L-734,217 (KdActivated = 5 nM and KdResting = 620 nM), can effectively inhibit ex vivo platelet aggregation at concentrations of drug that produce low levels of occupancy of the circulating platelet receptors. The potential clinical advantages of selective versus nonselective GP IIb/IIIa antagonists remain to be explored in clinical trials.


Assuntos
Plaquetas/efeitos dos fármacos , Ativação Plaquetária/efeitos dos fármacos , Inibidores da Agregação Plaquetária/farmacologia , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/antagonistas & inibidores , Azepinas/metabolismo , Azepinas/farmacologia , Ligação Competitiva , Plaquetas/metabolismo , Fibrinolíticos/metabolismo , Fibrinolíticos/farmacologia , Humanos , Peptídeos e Proteínas de Sinalização Intercelular , Oligopeptídeos/metabolismo , Oligopeptídeos/farmacologia , Peptídeos/metabolismo , Peptídeos/farmacologia , Peptídeos Cíclicos/metabolismo , Peptídeos Cíclicos/farmacologia , Inibidores da Agregação Plaquetária/metabolismo , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/isolamento & purificação , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/metabolismo , Sulfonamidas/metabolismo , Sulfonamidas/farmacologia , Tiazolidinas
6.
Chem Biol Interact ; 105(1): 35-52, 1997 Jun 06.
Artigo em Inglês | MEDLINE | ID: mdl-9233374

RESUMO

The rates of the non-enzymatic conjugation of the substituted aniline mustards, melphalan, chlorambucil and p-(N,N-bis(2-chloroethyl))toluidine with glutathione and thiosulfate were determined using nuclear magnetic resonance spectroscopy. Using this method, the disappearance of drug and the formation of both the mono-thioether and bis-thioether conjugates can be monitored directly. For glutathione conjugation, the rate constants for the formation of the first and second aziridinium intermediates were similar. With thiosulfate conjugation, the rate constant for the formation of the first aziridinium intermediate is greater than the rate constant for the formation of the second aziridinium. This demonstrates that the type of nucleophile has a significant influence on the overall alkylating activity of these bifunctional mustards. The bisthioether adduct formed from the reaction between p-(N,N-bis([2-13C]-2-chloroethyl))toluidine and glutathione and thiosulfate can be identified and scrambling of the 13C label in the product provides strong evidence that the alkylation must occur through an aziridinium intermediate.


Assuntos
Mostarda de Anilina/metabolismo , Glutationa/metabolismo , Tiossulfatos/metabolismo , Aziridinas/química , Radioisótopos de Carbono , Cinética , Espectroscopia de Ressonância Magnética/métodos , Melfalan/química
7.
Drug Metab Dispos ; 25(3): 355-61, 1997 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-9172954

RESUMO

L-738,167 is a potent and long-acting fibrinogen receptor antagonist and may be useful for treatment of chronic thrombotic occlusive disorders. The purposes of this study were to characterize the metabolism and disposition of L-738,167, and to investigate factors affecting its pharmacokinetic behaviors in dogs, one of the animal models used in pharmacological and toxicological studies. In vitro and in vivo experiments indicated that L-738,167 was not metabolized to any appreciable extent in dogs. Biliary excretion was found to be the major route (approximately 75%) of drug elimination. Following 1 and 3 micrograms/kg iv doses, blood pharmacokinetics of L-738,167 were linear. Total blood clearance (CLB) was much lower than hepatic blood flow, and the apparent volume of distribution at steady-state (Vdss,B) was comparable with blood volume. Blood pharmacokinetics in the dose range of 3-250 micrograms/kg were dose-dependent; both CLB and Vdss,B for L-738,167 increased markedly with increasing doses. However, the terminal half-life (t1/2) was dose-independent, with a mean value of approximately 4 days. L-738,167 was found to bind negligibly to dog plasma proteins. Determinations of whole blood (WB), platelet-rich plasma, and platelet-poor plasma concentrations after several intravenous doses of [3H]L-738,167 revealed significant concentration-dependent binding of the compound to platelets. Kinetic analysis of the platelet binding indicated that L-738,167 was bound to dog platelets with high affinity (apparent Kd approximately 1 nM platelet-poor plasma concentration) and relatively low capacity (approximately 70 nM WB concentration). Findings are consistent with the binding kinetics of L-738,167 to glycoprotein IIb/IIIa (GP IIb/IIIa) receptor, supporting that GP IIb/IIIa was the primary binding component on the platelets. It was concluded that the dose-dependent pharmacokinetics of L-738,167 were the consequence of the concentration-dependent drug-platelet binding. Due to this extensive platelet binding, L-738,167, when given in therapeutic doses or lower, resided primarily in the vascular compartment-the site of pharmacological action. At doses exceeding the receptor binding capacity, the excess amount or the unbound drug was eliminated rapidly. In all cases, the equally long t1/2 of L-738,167 was also a consequence of the high-affinity binding to platelets, in good agreement with its prolonged pharmacodynamic profile.


Assuntos
Azepinas/farmacocinética , Fibrinolíticos/farmacocinética , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/antagonistas & inibidores , Sulfonamidas/farmacocinética , Animais , Azepinas/sangue , Azepinas/farmacologia , Plaquetas/metabolismo , Proteínas Sanguíneas/metabolismo , Cães , Relação Dose-Resposta a Droga , Fibrinolíticos/sangue , Fibrinolíticos/farmacologia , Injeções Intravenosas , Masculino , Ligação Proteica , Sulfonamidas/sangue , Sulfonamidas/farmacologia , Trítio
8.
J Nucl Med ; 37(2): 307-11, 1996 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-8667067

RESUMO

UNLABELLED: Angiotensin II (ANG II) initiates a variety of physiological effects by binding to high affinity receptors. Two ANG II receptor subtypes, AT1 and AT2, have recently been identified. This study was undertaken to evaluate [11C]L-159,884, an AT1 subtype selective nonpeptide antagonist, as a potential PET tracer. METHODS: Carbon-11-L-159,884 was prepared by alkylation of the nor precursor with [11C]methyliodide and was studied for its in vivo binding characteristics, biodistribution and kinetics in mice. The effects of PD-123319, an AT2-selective ANGII antagonist, as well as those of alpha- and beta-adrenergic drugs on [11C]L-159,884 binding were investigated also. RESULTS: Administration of the AT1 antagonists resulted in dose-dependent inhibition of [11C]L-159,884 binding in the kidneys, the organ with the highest density of AT1 receptors. Inhibition was also observed in the lungs and the heart. Adrenergic drugs did not influence [11C]L-159,884 binding to AT1 receptors. Kinetic studies showed rapid tracer uptake in the liver, kidneys, lungs and heart. Excretion of the radioactivity occurred primarily through the intestinal tract (> 20% in 90 min), with less than 8% excreted through the urine. CONCLUSION: The results suggest that [11C]L-159,884 binds in vivo to AT1 receptors in mouse kidneys, lungs and heart. This radiotracer appears to be a promising candidate for studying ANG II receptors in vivo by PET.


Assuntos
Antagonistas de Receptores de Angiotensina , Imidazóis , Piridinas , Tomografia Computadorizada de Emissão , Animais , Radioisótopos de Carbono , Estudos de Avaliação como Assunto , Coração/diagnóstico por imagem , Imidazóis/farmacocinética , Rim/diagnóstico por imagem , Pulmão/diagnóstico por imagem , Masculino , Camundongos , Camundongos Endogâmicos , Piridinas/farmacocinética , Receptores de Angiotensina/análise , Distribuição Tecidual
9.
Appl Radiat Isot ; 47(2): 211-8, 1996 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-8852629

RESUMO

[11C]L-159,884 ([11C] N-[[4'[(2-ethyl-5,7-dimethyl-3H- imidazo[4,5-b]pyridin-3-yl) methyl] [1,1'-biphenyl]-2-yl] sulfonyl]-4-methoxybenzamide) and [11C]L-162,574 ([11C] N-[[4'[2-ethyl-5,7- dimethyl-3H-imidazo[4,5-b] pyridin-3-yl)methyl] [1,1'-biphenyl]-2-yl]sulfonyl]-3- methoxybenzamide), both potent and selective ligands for the AT1 receptor, were prepared by C-11 methylation of the corresponding desmethyl phenolic precursors. The radiotracers were purified by semi-preparative reverse-phase HPLC. Non-decay corrected radiochemical yields were 5 and 3% for L-159,884 and L-162,574 respectively, and the average specific activity was 2979 mCi/mumol at end-of-synthesis (EOS). The average time of synthesis was 18 min.


Assuntos
Angiotensina II/antagonistas & inibidores , Angiotensina I/metabolismo , Radioisótopos de Carbono/química , Imidazóis/metabolismo , Piridinas/metabolismo , Receptores de Angiotensina/metabolismo , Antagonistas de Receptores de Angiotensina , Cromatografia Líquida de Alta Pressão , Hidrocarbonetos Iodados/química , Processamento de Imagem Assistida por Computador , Imidazóis/síntese química , Marcação por Isótopo/métodos , Piridinas/síntese química , Tomografia Computadorizada de Emissão
10.
J Med Chem ; 33(3): 1009-14, 1990 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-2308133

RESUMO

Many cancer cells are resistant to chemotherapeutic treatment with mechlorethamine and other alkylating agents. These drug-resistant cells often show an increase in the intracellular concentration of glutathione and an increase in the activity of glutathione-S-transferase when compared to the sensitive cells. Both of these components are thought to be involved with inactivation of the drug either through conjugation with glutathione or by hydrolysis. NMR spectroscopy was used to monitor the nonenzymatic conjugation of mechlorethamine with glutathione. Several intermediates along the pathway to the doubly glutathione substituted mustard, including both mustard-aziridinium adducts, can be observed. The assignment of the 1H NMR spectrum of these adducts are presented. At 30 degrees C, pH 7.0, no hydrolyzed mustard was detectable. With the use of 13C-labeled mustard, the conjugation reaction can be shown to proceed through an aziridinium intermediate rather than by direct nucleophilic substitution.


Assuntos
Glutationa , Mecloretamina , Espectroscopia de Ressonância Magnética
11.
Clin Chem ; 31(4): 601-5, 1985 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-3978795

RESUMO

The European standardized method for measuring porphobilinogen synthase (PBGS, EC 4.2.1.24) activity in peripheral erythrocytes is widely used in epidemiological studies of low-level Pb absorption. We have modified it to include activation with dithiothreitol (DTT). In children with concentrations of Pb in whole blood ranging from 0.29 to 1.93 mumol/L, we found the following statistically significant correlations (r): blood Pb vs nonactivated PBGS activity = -0.773 (p less than 0.005); blood Pb vs DTT-activated PBGS activity = -0.265 (p less than 0.005); blood Pb vs the ratio of DTT-activated/nonactivated PBGS activity = +0.818 (p less than 0.005). At a DTT-activated/nonactivated PBGS activity ratio of 1, which indicates no Pb-dependent inhibition of PBGS, a corresponding blood Pb concentration of 0.24 mumol/L (50 micrograms/L) would be predicted. In individuals with hematological disorders, the DTT-activated/nonactivated ratio better predicted blood concentration of Pb than did the nonactivated PBGS activity, and largely compensated for the high variability in PBGS activity. We also describe techniques to minimize contamination by Zn and Pb and to stabilize enzyme activity during collection, transport, storage, and analysis of samples.


Assuntos
Ensaios Enzimáticos Clínicos , Eritrócitos/enzimologia , Intoxicação por Chumbo/diagnóstico , Sintase do Porfobilinogênio/sangue , Adolescente , Anemia Falciforme/enzimologia , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Chumbo/sangue , Masculino , Protoporfirinas/sangue , Talassemia/enzimologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...